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Natural killer (NK) ~ cells, a  subpopulation of lymphocytes with the ability to lyse 
tumor cells, have been demonstrated in a  variety of experimental animal species and 
in man (1, 2). One of the characteristics of NK-cell activity in mice and rats is that it 
is first detectable at 3-4 wk of age, reaches a  peak at 5-8 wk, and declines thereafter 
to low or undetectable levels. Some insight into the factors regulating the expression 
of NK activity has been provided by the observation that  inoculation of tumor cells 
(3),  viruses  (3-5),  and  bacterial  products  (3,  6)  into  mice  led  to  augmentation  or 
reappearance  of  NK  activity  within  3  d.  A  large  number  of the  materials  that 
augmented NK cytotoxicity are known to be able to induce interferon  (IF), and the 
possibility  that  IF  mediated  the  boosting of NK activity was  therefore considered. 
Indeed, direct evidence is now available for the boosting of NK activity in vivo and 
in vitro by type I IF that has been induced by Newcastle disease virus (NDV) and by 
other common IF inducers  (7, 8). 
The mechanism for augmentation of NK activity by inoculation of tumor cells is 
less clear. Trinchieri et al.  (9) recently reported that human lymphocytes cultured in 
vitro with  tumor cells  for  18-24  h  produced  soluble  factors that  can  augment  NK 
activity  as  well  as  display  antiviral  properties.  In  the  light  of these  findings,  we 
initiated  the  present  study  to determine whether  in  vivo inoculation  of tumor cells 
that led to increased NK activity (3) could also induce detectable circulating levels of 
IF. We have found that several syngeneic and allogeneic tumor cells induced remark- 
ably high serum levels of IF and that the kinetics of IF induction was similar to that 
of boosting of NK activity in  the spleen. The IF induced by tumor cells in vivo was 
acid labile and required  prolonged incubation  with  L  cells to induce full protection 
against virus challenge, thus resembling type II IF (10). 
Materials and Methods 
Mice.  Female  BALB/c,  C57BL/6,  CBA/N,  and  DBA/2  mice,  as  well  as  BALB/c  nude 
mice,  were obtained  from  the  Rodent  and  Rabbit  Production  Section,  Division of Research 
Services, National Institutes of Health, Bethesda, Md. 
i Abbreviations used in this paper: IF,  interferon(s); LCMV,  lymphocytic choriomeningitis virus;  MLV, 
Moloney leukemia virus; MSV, murine sarcoma virus; NDV, Newcastle disease  virus; NK, natural killer; 
RLV, Rauscher leukemia virus. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  • VOLUME  151, 1980  781 782  BOOSTING OF NATURAL KILLER  ACTIVITY AND INTERFERON 
Cell Lines.  Most of the in vivo and in vitro tumor cell lines have previously been described 
(I I). Ascitic and tissue culture tumor lines are designated by the suffixes A and TC, respectively. 
The BALB/c-transformed cell line, WM-7, derived from a spontaneous fibrosarcoma and the 
same cell line infected with Rauscher leukemia virus, R-WM-7, were provided by Dr. I. AI- 
Ghazzouli, Microbiological Associates,  Walkersville, Md. (12). 
Viruses.  Murine sarcoma  virus  (MSV),  Moloney leukemia virus  (MLV),  and  Rauscher 
leukemia virus (RLV) were obtained from the Virus Cancer Program of the National Cancer 
Institute (Bethesda,  Md.) through the courtesy of Dr. Jack Gruber. Ter A type C virus, shed 
from  a  spontaneous C3H/HeICRF ovarian teratoma cell  line, was  provided by Dr.  W. J. 
Martin, Food and Drug Administration,  Bureau of Biologics, Bethesda, Md. (13). Lymphocytic 
choriomeningitis virus (LCMV), attenuated Armstrong strain CA1371, was  provided by Dr. 
W. Rowe, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and influenza 
virus, strain A/Port Chalmers, was obtained from Dr. F. A. Ennis, Food and Drug Administra- 
tion, Bureau of Biologics. NDV was prepared in fertile chick eggs as previously described (14). 
Antibodies to IF.  Two sources of anti-mouse type I IF globulin were used in this study. One 
was  the  gift  of Dr.  I.  Gresser,  Institut de  Recherches  Scientifiques sur le Cancer, Villejuif, 
France, and its specificity has been described in detail elsewhere  (7). The other anti-IF globulin 
was provided by Dr. K. Paueker, The Medical College of Pennsylvania,  Philadelphia, Pa. Both 
reagents were produced against purified mouse IF induced in L cells by NDV. 
Virus-induced Serum IF.  BALB/c mice, inoculated with NDV, were bled for serum IF 10 h 
later, as previously described (14). 
Inhibition of  Protein Synthesis.  RLd~  1 ascites tumor cells were incubated with a 10  -5 M solution 
of pactamycin (15) for 45 min at 37°C. The cells were then washed twice with medium before 
inoculation into mice. 
In  Vivo Challenge with  Tumor Cells or Viruses.  Tumor cells or viruses detected in RPMI21640 
medium (Grand Island Biological  Co., Grand Island, N. Y.) were inoculated intraperitoneally 
in RPMI-1640 medium. Each mouse received 1 X  10  7 viable tumor cells or 0.2 ml of a stock 
solution of virus. At various intervals after inoculation, three mice per group were bled and 
their pooled sera were tested for circulating levels of IF. The spleen cells from the same mice 
were also pooled and tested for NK activity. 
Titration of IF.  Antiviral activity in the  serum samples was  measured by the  degree  of 
inhibition of the cytopathic effect caused by vesicular stomatitis virus (14). 
Measurement of NK Activity.  Spleen cells, pooled from three mice, were  incubated at 200:1 
and 50:1 ratios with  51Cr-labeled  RLdl  tumor target  cells  for  4  h  at  37°C,  as  previously 
described  (7). Cryopreserved target cells were used to minimize day-to-day variation in the 
assay and the base-line SlCr release was determined by the use of unlabeled autologous tumor 
cells  in place of lymphoid cells.  By  using a  combination of cryopreserved  tumor cells  and 
autologous control cultures, the base-line lysis was consistently between 5 and 8%  and the 
median standard error was  0.6%. Levels  of cytotoxicity of 2%  or more above the  base line 
consistently were significantly different from the controls by the Student's t test  (P <  0.05). 
The percent cytotoxicity was calculated as follows: 
cpm released from experimental group -  cpm released from autologous control ×  100 
total cpm incorporated. 
In all the tables, only the 200:1 ratio was reported because the lower percent cytotoxicity was 
dose responsive and the lower ratio yielded a similar pattern of results. 
Results 
In  Vivo Boosting  of NK Activity  and Induction  of IF by Mouse  Tumor Cells.  12-wk-old 
BALB/c  and BALB/c  nude mice, expected  to  have  low  levels of spontaneous NK 
activity, were  inoculated intraperitoneally with  either  RLdl,  RBL-5,  or  EL-4  G+ 
ascites tumor cells. At various times after inoculation, sera were obtained to test for 
the presence of circulating IF, and the spleen cells were tested for NK activity. Three 
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TAaLE  I 
Boosting of NK Activity and Induction of IF by Mouse Tumor Cells 
Experi- 
ment  Recipient  Strain of  Inoculum*  origin 
Percent cytotoxicity (units of IF/ml serum) 
ld  2d  3d 
BALB/c  None  3.3 (<5)  2.9 (<5)  4.1 (<5) 
Medium  2.4 (<5)  2.6 (<5)  4.6 (<5) 
RIll A  BALB/c  18.4 (398)  15.8 (1,995)  5.9 (<5) 
RBL-5 A  C57BL/6  18.7 (501)  17.6 (1,000)  5.2 (<5) 
EL-4 G+ A  C57BL/6  15.9 (126)  18.8 (1,259)  16.1 (133) 
BALB/c 
Nude 
None  1.8 (<5)  2.4 (<5)  2.6 (<5) 
Medium  1.8 (<5)  2.4 (<5)  2.8 (<5) 
RLc~I A  BALB/c  24.5 (2,511)  19.4 (1,258)  4.8 (<5) 
RBL-5 A  C57BL/6  16.8 (3,981)  25.4 (3,162)  12.9 (<5) 
EL-4 G+ A  C57BL/6  20.1 (630)  18.3 (1,995)  3.5 (<5) 
3  BALB/c  None  4.5 (<5)  3.6 (<5)  3.3 (<5) 
Medium  3.6 (<5)  2.7 (<5)  4.0 (<5) 
RLdl A  BALB/c  23.8 (6,3t0)  26.9 (3,162)  I8.3 (10) 
RIAI A (pact.):]:  BALB/c  19.2 (6,310)  22.3 (1,000) 
RIll TC  BALB/c  4.1 (<5)  21.7 (1,000) 
RBL-5 A  C57BL/6  21.2 (50,118)  20. I (6,301)  5.7 (32) 
RBL-5 TC  C57BL/6  18.7 (3,981)  15.6 (3,162) 
* 107 tumor cells were inoculated intraperitoneally into 12-wk-old mice. 
RL~I tumor cells were incubated with  10  -5 M of pactamycin  for 45 min at 37°C and washed before 
inoculation into mice. 
of augmenting  NK  activity in  both  conventional  and  nude  mice,  and  substantial 
increases were seen within  1 d  of challenge. The activity was  transient  and  usually 
declined or returned  to base-line levels by day 3.  Serum  antiviral activity was also 
induced by these tumor-cell lines and often reached remarkably high levels. For each 
cell line, there was  a  close correlation between  the kinetics of augmentation  of NK 
activity and  the kinetics of induction  of IF. The  tissue culture  lines of RIdl  and 
RBL-5  tumor cells induced similar levels of NK activity and  IF as the ascitic lines. 
Because the tumor cells used in these experiments were lymphomas that might have 
the  ability to  produce  lymphokines  themselves,  it  was  important  to  rule  out  that 
possibility. Therefore,  mice were  inoculated  with  RLc~I  tumor  cells that  had  been 
pretreated with pactamycin for 45 min at 37°C  to inhibit protein synthesis (Table I). 
This treatment,  which  has been  shown  to completely and  irreversibly block protein 
synthesis, had  no adverse effect on  the ability of RI~  1 tumor cells to augment  NK 
activity or to induce IF. The IF thus appeared to be host derived. 
The kinetics of tumor cell-induced augmentation of NK activity and induction of 
circulating levels of IF were then  more closely examined. As seen in a  representative 
experiment in Table II, 56  U  of IF/ml  were already detectable in the serum  at  4  h 
after challenge with  RL~ 1 tumor cells but  no significant rise in NK cells was seen. 
The two activities rose steadily thereafter to peak at  15-24 h.  By day 3, the IF level 
had declined and the NK activity had correspondingly decreased, and both activities 
approached background levels by day 6. 
Challenge  of BALB/c  Mice  with  a  Variety  of  Tumor  and  Normal  Cells.  To  further 
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TABLE II 
Early Detection of NK Cells and Circulating IF after RLc~  I  Tumor Cell 
Inoculation 
Percent cytotoxicity  Time after RLdl inoculation*  units of IF/ml serum) 
0 h  2.8 (<5) 
4 h  3.4 (56) 
8 h  10.5 (177) 
15 h  27.2 (3,162) 
24 h  26.2 (5,623) 
3 d  15.6 (446) 
6 d  5.0 (<5) 
* 107  ascites tumor  cells were inoculated  mtraperitoneally into  12-wk-old 
BALB/c mice. 
TABLE  III 
Boosting of NK Activity and Induction of IF by Various Tumor and Normal 
Cells 
Strain of ori-  Inoculum*  gin 
Percent cytotoxicity (units of IF/ 
ml serum) 
ld  3d 
None  2.3 (<5)  0.8 (<5) 
LSTRA A  BALB/c  2(I.4 (1,000)  16.7 (1,259) 
L1210 A  DBA/2  16.6 (2,511)  9.7 (631) 
P815 A  DBA/2  19.7 (l,000)  10.1 (25) 
YAC TC  A/Sn  21.4 (478)  5.6 (<5) 
WM-7 TG  BALB/c  2.9 (<5)  1.8 (<5) 
R-WM-7 TC  BALB/c  3.9 (<5)  2.1 (<5) 
L929 TC  C3H  2.5 (<5)  2.2 (<5) 
Thymus cells  CBA/N  8.2 (5)  3.1 (5) 
Spleen cells  CBA/N  2.0 (<5)  2.4 (<5) 
Thymus cells  C57BL/6  10.1 (64)  6.3 (<5) 
Spleen cells  C57BL/6  2.7 (<5)  2.4 (<5) 
* 107 cells were inoculated intraperitoneally into 12-wk-old BALB/c mice. 
mice were  inoculated with  a  variety of syngeneic and allogeneic tumor or  normal 
cells. One of four experiments performed is shown in Table III. Most of the tumor-cell 
lines activated the two activities within 1-3 d; however, WM-7, R-WM-7, and L  929 
cells did not. As previously described (3), allogeneic thymus cells consistently caused 
a small rise in NK activity. This was accompanied by a low but detectable rise in IF. 
Allogeneic spleen cells, on the other hand, had no stimulatory effect on NK activity 
or IF levels. Although there  was  not a  good  quantitative relationship between the 
degree of NK boosting and IF level produced by the various inocula, all cells capable 
of boosting NK activity also induced some increase in serum IF. 
Challenge with  Viruses.  To ascertain whether type C  viruses that often contaminate 
tumor-cell lines might  be  responsible for  the  observed  activation of NK cells  and 
induction of IF,  BALB/c mice were inoculated with  MSV,  MLV,  RLV,  or Ter A 
virus  and  then  tested  for  four  consecutive days  (Table  IV).  For  comparison,  the 
nononcogenic viruses, LCMV and influenza A, were also studied. MSV augmented J.  Y.  DJEU,  K.-Y.  ttUANG,  AND  R.  B.  HERBERMAN 
TABLE  IV 
Effect of Various Viruses on Boosting of NK Activity and on Induction of IF 
785 
Inoculum* 
Percent cytotoxicity (units of IF/ml serum) 
ld  2d  3d  4d  6d 
None  12.1  (<10)  7.4 (<10)  10.1  (<10)  12.8  (<10)  9.2 (<10) 
Tumor cells 
RLdl A  25.0 (1,584)  25.8 (11,481)  15.2  (50l)  14.3  (10)  8.7 (<10) 
RBL-5 A  16.4  (5,011)  20.4 (3,981) 
Type C  viruses 
MSV  25.3 (891)  17.3 (49)  14.7  (<I0)  9.7 (<10) 
MLV  12.0  (<10)  10.3  (<10)  11.0  (<10)  13.9 (<10) 
RLV  t0.3 (<10)  8.8 (<10)  5.8 (<10)  14.2 (<10) 
TerA  9.4 (<10)  7.1  (<10)  9.2 (<10)  10.1  (<10) 
Other viruses 
LCMV  8.8 (<10)  6.5 (10)  30.9 (158)  31.3 (25)  10.7  (10) 
Influenza A  6.8 (<10)  10.4  (<10)  27.7 (10)  37.7 (64)  17.1  (10) 
*  107 tumor cells or 0.2  ml of a  stock solution of virus were inoculated intraperitoneally  into  12-wk-old 
BALB/c mice. 
TABLE  V 
Comparison of the Characteristics of Tumor-induced IF with ND V-induced IF 
Experi-  Treatment 
ment 
Units of IF/ml serum 
NDV-IF  RL~I-IF  RBL-5-IF 
None  56,234  5,623  6,309 
56°C,  lh  <10  316  251 
Anti-viral activity with HeLa cells  <10  <10  <10 
pH 3.0  50,118  <10  <10 
pH 6.0  4,778  5,523 
pH 9.0  5,011  4,786 
Incubation with IF* 
1 h  50,118  <10  <10 
4 h  50,118  398  2,511 
8 h  5,011  5,523 
12 h  5,011  6,309 
None  63,095 
Normal globulin 
1:400  60,200 
Anti-IF (Paucker) 
1:400  <10 
1:800  <10 
None  17,782 
Normal globulin 
10  -4  17,782 
10  -5  17,782 
10  -~  18,000 
Anti-IF (Gresser) 
10 -4  <10 
10  -s  <10 
10  -~  3,981 
1,000 
794 
<10 
<10 
7,585 
6,855 
6,855 
7,079 
<10 
<10 
<10 
* L  929 cells were incubated with various dilutions of each IF for the time period  indicated and 
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NK activity and induced serum  IF. However, as previously described, other type C 
viruses  had  no  effect  on  the  two  activities.  LCMV  and  influenza  viruses  readily 
activated the two functions, but with a  later response than that seen with MSV or 
tumor cells. Both activities peaked at day 3 after virus challenge and peak levels of IF 
were much lower than those seen after tumor challenge. 
Characteristics of Tumor-induced IF.  The characteristics  of the  antiviral  activity in 
the  serum  samples  collected  24  h  after  RLc~I  or  RBL-5  tumor  challenge  were 
compared with  those of type I  IF  induced  in  vivo by NDV  (Table V).  The virus- 
induced and tumor-induced IF lost appreciable activity after incubation for 56°C for 
1 h, and both preparations  exhibited  species specificity in  their  inability to protect 
human  HeLa cells  from  virus  challenge.  However,  the  two  types of IF  specimens 
differed in other respects.  Unlike virus-induced IF, the tumor-induced IF was labile 
at pH 3.0. In addition, preincubation with virus-induced IF for 1 h fully protected L 
929 cells against VSV, but a considerably longer incubation period was required for 
tumor-induced IF. Although the pH lability of the tumor-induced IF and the need 
for prolonged incubation to induce viral  resistance were characteristic of type II IF 
(10), the antiviral activity of the tumor-induced IF was readily neutralized by antisera 
to virus-induced IF obtained from two sources. This led us to consider the possibility 
that  the  samples  collected  at  24  h  might  contain  a  mixture  of virus-induced  and 
tumor-induced  IF.  Samples  taken  at  various  times  after  RL~I  tumor  inoculation 
between 4 and 48 h were therefore tested for acid and heat lability as well as sensitivity 
to antivirus-induced  IF. All the samples were found to have the same properties as 
listed above, which made it likely that the anti-IF are not type specific. 
Discussion 
Our study clearly indicates that tumor cells  in addition to other inocula that have 
previously been shown to boost NK activity (3-8), can induce high levels ofcirctilating 
IF  in  vivo. This  is  analogous to  the  findings  of Trinchieri  et  al.  (9)  who  detected 
antiviral activity in the supernates of human lymphocytes cultured in the presence of 
tumor cells. These observations are consistent with the hypothesis that augmentation 
of NK activity, regardless of the type of stimulus, is mediated by induction of IF. 
The  appearance  of circulating  IF  coincided  well  with  the  development  of NK 
activity in  tumor-inoculated  mice.  Both  activities  peaked  at  24-48  h  and  usually 
declined by 3 d. In contrast, peak activities after virus challenge were seen only after 
3 d, and base-line levels were reached after 6 d. The kinetics of response to tumor cells 
were, in fact, earlier than those previously reported from our laboratory (3), and the 
differences  in  kinetics  are  not  yet  clear.  The  previous  study  was  performed  with 
irradiated tumor cells and it is possible that this altered the kinetics. The health of the 
mice and  their  previous exposure to various IF inducers,  such  as  viruses,  may also 
affect the kinetics.  Other investigators have observed that tumor cells  can induce IF 
in vivo. The kinetics of IF production as reported by Svet-Moldavsky et al.  (16) and 
Skurkovich et al.  (17) were very similar to those reported here. Svet-Moldavsky et al. 
(18),  however,  detected  a  small  rise  in  circulating  IF  after  intravenous  transfer  of 
allogeneic spleen cells, which differs from our data. This may be a result of the route 
of inoculation, because these authors observed a difference in the level of IF production 
by intravenous  and  intraperitoneal  inoculation.  We  found  that  allogeneic  thymus J.  Y.  DJEU, K.-Y. HUANG, AND R.  B.  HERBERMAN  787 
cells caused some rise in NK cells and IF, but both levels were much lower than those 
observed with tumor cells. 
The antiviral activity in the serum of mice inoculated with tumor cells met several 
criteria  for mouse  IF.  It  exhibited  heat  lability,  had  the  ability  to  stimulate  viral 
resistance in indicator L cells, had species specificity, and was neutralized by anti-IF 
globulin. The IF induced by tumor cells resembled type II IF in being acid labile. In 
addition, it required 8 h of incubation with L cells to induce full protection similar to 
type II IF induced by staphylococcal enterotoxin A  (10). 
The possibility that IF induction and NK boosting by tumor cells might be a result 
of  virus  contamination  of  the  tumor  lines  was  evaluated.  Because  a  variety  of 
nononcogenic  viruses  that  are  frequent  contaminants  of mice and  tumor-cell  lines 
have been shown to boost  NK function  (3), probably by their ability to induce IF, 
this is of particular concern.  In addition, most of the tumor-cell lines express type C 
viruses and these might cause the observed effects. This latter possibility is unlikely 
because our previous (3) and present findings showed that a  variety of type C  viruses 
failed to boost NK ceils or induce IF. MSV type C  virus was the only exception, but 
it is possible that the stimulatory effect of this virus has been a  result of the use of a 
crude  preparation  that  was  made  from  a  pool  of solid  tumors  that  was  simply 
homogenized and centrifuged to remove most cell debris.  It is thus quite likely that 
the  MSV  preparation contained  tumor antigens  and other cell contaminants.  It is 
also possible that MSV has the ability to rapidly transform cells that could then boost 
NK activity. Still another possibility is that it is contaminated with a  nononcogenic 
virus. Nononcogenic viruses, however, induced NK cells and IF in vivo with kinetics 
distinctly separate from those induced by MSV or tumor cells. Moreover, the tumor- 
induced  IF showed antiviral properties resembling type II IF rather than type I  IF. 
Interestingly enough, the IF induced by in vitro culture of human lymphocytes with 
tumor cells was found to have characteristics largely of type I IF as characterized by 
gel filtration and acid stability (9). 
The cell type that is responsible for the production of IF is not yet known. Trinchieri 
et  al.  (9),  presented  some  evidence  for  IF  production  by  NK cells  themselves,  in 
response to  tumor cells  in  vitro.  However,  macrophages appeared  to  be the  main 
source of IF (19)  by poly inosinic:poly cytidylic acid boosting of mouse NK activity. 
Similarly, macrophages are required in the Bacille Calmette-Gu~rin boosting of NK 
activity (6).  In this study, we found that nude mice could respond to tumor cells in 
vivo by high  levels of IF production,  which  suggests that  mature T  cells were not 
involved. 
The finding that all of the tumor cell-induced IF activity was acid labile and that 
it required prolonged binding to indicator cells for full protection indicates that type 
II mouse IF also has the ability to strongly boost NK activity. These data suggest that 
one of the  earliest  events triggered  in  the host  by recognition  of tumor cells is  the 
production of immune IF that has the ability to promote lysis of the relevant target 
cells.  Indeed,  many of the  tumor cells,  including  thymus cells,  that  are capable of 
boosting NK activity and inducing IF are sensitive to NK lysis, and it is possible that 
the boosting of the two activities is a  result of rapid and specific recognition of NK 
target-cell structures. It is reasonable to interpret these data by assuming that the NK 
cells themselves may be responsible for IF production,  and  it  will  be important  to 
directly examine this point.  This postulated sequence of events support  a  potential 788  BOOSTING  OF NATURAL KILLER ACTIVITY AND INTERFERON 
role of NK cells in natural  and nonthymus-dependent defenses against  tumors, even 
when spontaneous levels of NK activity are low.  Recognition of NK-sensitive tumor 
cells could, within hours, result in appreciable levels of antitumor activity in the host. 
Summary 
Conventional  and  nude  mice inoculated  with  syngeneic or allogenic  tumor cells 
developed a rapid rise in serum interferon  (IF) levels, peaking within 24 h. Within the 
same  period,  natural  killer  (NK)  activity  was  readily  boosted  in  the  spleen.  Both 
activities usually declined at 3 d. Cells that lacked the ability to augment NK activity 
also failed to induce detectable levels of IF. The boosting of IF and NK functions did 
not  appear  to  be  a  result  of contamination  of the  tumor  lines  by  viruses  because 
inoculation of several type C  viruses into normal mice had no effect, and other viruses, 
like  lymphocytic choriomeningitis  virus  and  influenza,  elevated  IF  and  NK  levels 
with a  significantly later kinetics, peaking 3-4 d. The IF induced by tumor cells was 
heat and acid labile, species specific, and appeared to be in the type II class, although 
it was susceptible to antisera against  Newcastle disease virus-induced IF. These data 
suggest that an early, nonthymus-dependent consequence of tumor-cell recognition is 
the production of IF, which, in turn, activates NK cells to lyse the tumor cells. 
Received for publication  27 November 1979. 
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